One Lambda, Inc. Receives CE Mark Approval for C1qScreen Assay and Launches Assay in Europe

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CANOGA PARK, Calif.--(BUSINESS WIRE)--One Lambda Inc., part of Thermo Fisher Scientific and a leading producer of in vitro diagnostic products for the human leukocyte antigen (HLA) transplant community, has received CE mark approval in Europe for its C1qScreen™ assay. The assay, which was recently cited in the New England Journal of Medicine for its use in a kidney graft survival study (New England Journal of Medicine 360 (2013): 1215-1226), is now available in all CE mark-conforming countries, enabling European HLA clinics and laboratories to immediately use it during transplant diagnostic procedures.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC